Development Drug Trials Genetics Trials 
Pharmaceutical Technology
JUNE 15, 2023
But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Pharma R&D teams are solving this problem by leveraging the power of artificial intelligence (AI) in clinical trials to save time and money. Food and Drug Administration approval.
Drug Discovery World
MAY 21, 2024
Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. These targets, along with many others, are universally deemed as ‘difficult-to-drug’ targets.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
MAY 16, 2023
Clinical trials for pulmonary fibrosis are being conducted to evaluate the effectiveness of novel therapies and interventions, providing hope for improved outcomes in the future. Exposure to substances like asbestos, silica dust and certain chemicals has been linked to the development of pulmonary fibrosis.
Drug Discovery World
JUNE 20, 2024
Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for MND.
pharmaphorum
AUGUST 25, 2022
When cirrhosis complications develop, some will be lucky enough to be listed for a transplant. Obesity, diabetes, and genetics are the primary drivers, and COVID is about to make this exponentially worse. Dozens of companies are working at various stages of drug development. This disease is touching more of us every day.
XTalks
SEPTEMBER 11, 2020
Expanding minority Americans’ access to care and clinical trials isn’t just the right thing to do. Clinical Trials Don’t Reflect Demographics. Disease doesn’t discriminate, and researchers understand different populations react differently to drugs. Why, then, are clinical trials so stubbornly homogeneous?
XTalks
FEBRUARY 25, 2022
There has been increasing awareness around the need for improving inclusion and diversity in clinical trials. They are also at a high risk of developing heart disease and stroke. times greater risk of developing kidney disease and are 2.3 times greater risk of developing kidney disease and are 2.3
Expert insights. Personalized for you.
130 
Let's personalize your content